(Q33820416)

29 July 2017

1 reference

title

Treatment of polycythaemia vera and essential thrombocythaemia (English)

1 reference

29 July 2017

1

A Tefferi

1 reference

29 July 2017

M N Silverstein

2

1 reference

29 July 2017

publication date

1 December 1998

1 reference

Best Practice and Research: Clinical Haematology

29 July 2017

published in

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

769-785

1 reference

Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Aspirin and risk of bleeding in patients with thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Essential thrombocythemias. Clinical evolutionary and biological data

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

The in vitro and in vivo effect of recombinant interferon alpha-2a on circulating haemopoietic progenitors in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Complications and causes of death in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Recombinant interferon alpha-2b in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Childbearing age patients with essential thrombocythemia: should they be placed on interferon?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Treatment of polycythemia vera with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Clinical course of essential thrombocythemia in 147 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Role of interferon alpha-2a in the treatment of polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Acute leukemia as a natural sequel to primary thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Long-term interferon therapy for thrombocytosis in myeloproliferative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Essential thrombocythemia and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Low-dose aspirin in polycythaemia vera: a pilot study. Gruppo Italiano Studio Policitemia (GISP)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

In vivo and in vitro inhibitory effect of alpha-interferon on megakaryocyte colony growth in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Essential thrombocythemia. Clinical characteristics and course of 61 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Megakaryocyte and erythroid colony formation in essential thrombocythaemia and reactive thrombocytosis: diagnostic value and correlation to complications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Metabolic and Therapeutic Effects of Hydroxyurea in Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Uncontrolled thrombocytosis in chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Interferon-alpha in the treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant clone

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Transient neurologic and ocular manifestations in primary thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Polycythaemia and thrombocythaemia in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Interferon treatment in polycythaemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Use of radioactive phosphorus in haematology

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Interferon-alpha 2b: a new treatment for polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Anagrelide: A New Drug for Treating Thrombocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

The effects of anagrelide on human megakaryocytopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

New drugs in essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Successful treatment of essential thrombocythemia with alpha interferon during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2898%2980038-3

7 January 2021

10.1016/S0950-3536(98)80038-3

Identifiers

DOI

1 reference

29 July 2017

1 reference